Med BioGene Shareholders Approve Commercialization Deal with Precision Therapeutics
April 13, 2011
Med BioGene Shareholders Approve Commercialization Deal with Precision Therapeutics
Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.